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Abstract 19 
Human exposure to polycyclic aromatic hydrocarbons (PAHs) often occurs through the oral 20 
route during hand to mouth transfer of contaminated soils. It is accepted that PAH bioavailability 21 
from ingested soils will vary between soils, however, the nature of this variation is not well 22 
characterized. Here, we used the juvenile swine model to link external exposure to internal 23 
benzo[a]pyrene (BaP) and anthracene exposure following oral PAH ingestion of 27 different 24 
real-world soils, soots, or spiked artificial soils. Internal exposure of BaP and anthracene, 25 
represented by area under the plasma-time curve (AUC), did not correlate to soil concentration in 26 
real-world soils. However, soil concentration correlated with internal exposure in spiked 27 
artificial soil. Point of departure (POD) modeling identified soil PAH concentrations greater than 28 
1,900 mg kg-1 as the concentration where internal exposures become proportional to external 29 
doses. Alternatively, BaP and anthracene internal exposure below 1,900 mg kg-1 averaged 21% 30 
of external exposure but we could not detect a trend between internal and external exposure at 31 
these low concentrations.  Weak correlations between soil:simulated gastrointestinal fluid PAH 32 
partitioning and AUC values indicate that desorption from soil does not play a large role in 33 
influencing internal exposure of PAHs. We propose four PAH risk assessment options: (i) 34 
assume 100% bioavailability, (ii) assume constant internal exposure below 1,900 mg kg-1, (iii) 35 
assume <100%, e.g. 21%, bioavailability below 1,900 mg kg-1, or (iv) model internal exposure 36 
through AUC versus soil characteristic relationships.  In our opinion, our data best supports 37 
option (ii) because we could not detect an increase in AUC with increasing soil concentrations 38 
and our best efforts at (iv) do not robustly predict uptake of different PAHs.    39 
Keywords: toxicokinetics, swine, PAHs, soil  40 
Introduction 41 
 Human exposure to polycyclic aromatic hydrocarbons (PAHs) commonly occurs through 42 
ingestion of impacted soil. The absorption and bioavailability of PAHs has been studied 43 
extensively (see Ramesh et al. 2004 for a thorough review), and it is widely accepted that oral 44 
bioavailability of PAHs can differ when present in different media. The observed bioavailability 45 
of PAHs varies between different soil types (Stroo et al., 2000, Kadry et al., 1995, Juhasz et al., 46 
2014, James et al., 2011). These differences arise from contaminant weathering in soil, as well as 47 
soil characteristics, which may include soil particle size or chemical partitioning (James et al., 48 
2011, Juhasz et al., 2014, Duan et al., 2014). However, rarely has a wide range of soils been fed 49 
to a mammal and PAH bioavailability assessed. Here we fed 19 soils, 4 artificial soils and 4 soot 50 
samples to juvenile swine. We used plasma concentrations of parent PAHs to calculate 51 
bioavailability and elimination/absorption rates. Using a large data set is essential to 52 
characterizing what occurs when mammals ingest PAHs.   53 
Once ingested, PAHs transfer from the gastrointestinal tract to systemic circulation. 54 
Transfer of PAHs into circulation occurs concurrent with lipids (Stavric and Klassen, 1994), and 55 
it has been theorized that PAHs are transferred via chylomicron formation within enterocytes and 56 
transferred into lymph, which would allow PAHs to bypass the liver and first pass elimination 57 
(Hussain et al., 1996, Busbee et al., 1990). However, a study done in lymph and bile duct 58 
cannulated rats determined that about 80% of absorbed PAHs transfer to circulation via hepatic 59 
portal transport, rather than lymph (Laher et al., 1984). A more recent study confirms these 60 
findings, concluding that approximately twice the PAHs entering into circulation cross through 61 
hepatic portal transfer rather than through chylomicron formation and transport through the 62 
lymphatic system (Kim et al., 2012).  Thus, the majority of ingested PAHs enter the body via the 63 
portal vein, to the liver and from there to systemic circulation 64 
 Rapid metabolism of PAHs can confound quantification of PAH uptake following oral 65 
exposure. For example, the liver extensively metabolize PAHs (Ramesh et al., 2004). Analyzing 66 
unlabeled metabolites in an organism is a very daunting task because PAHs are a family of 67 
compounds, e.g. there are typically at least 9-16 PAHs of interest present in an impacted soil, and 68 
each compound can convert into more than one metabolite (Ramesh et al., 2004). Using 14C 69 
labeled compounds eliminates the complicated analysis necessary for unlabeled compounds; 70 
however a number of factors make 14C analysis unfavorable for use in PAH bioavailability. First, 71 
14C labeled PAHs may overestimate risk to PAHs, as most absorbed PAHs metabolize to inert 72 
metabolites that excrete quickly (Ramesh et al., 2004). Additionally, the use of 14C labeled 73 
compounds is limited to spiked soil, and it would be difficult to compare results to those 74 
obtained from naturally impacted soils. 75 
 Previously, systemic PAH metabolites were thought to be best estimate of PAH 76 
bioavailability(Ramesh et al., 2004). These metabolites arise, in a large part, from liver mono-77 
oxygenase enzymes such as CYP 1A1, CYP 1A2, and CYP 1B1. It was initially assumed that 78 
toxic metabolites form in the liver and transport in systemic circulation to cause peripheral 79 
toxicity. However, animal studies using inbred mouse strains observed that circulating 80 
metabolites do not cause of bone marrow and spleen toxicity (Legraverend et al., 1983, Uno et 81 
al., 2004, Galvan et al., 2005). This is a reasonable observation, as toxic metabolites of PAHs 82 
have epoxide groups present on the compound, and as such, are highly reactive and would not 83 
travel far in circulation without reacting with epoxide hydrolase or a cellular component. These 84 
results should not be taken to imply that the CYP family is unimportant for toxicity, but rather 85 
that the first pass effect in which much of the ingested PAHs are metabolized as the portal vein 86 
empties into the liver acts as a detoxification reaction.  Thus, the assessment of parent PAHs in 87 
the systematic circulation may be a better estimate of non-hepatic toxicity after oral exposure. 88 
Animals, acting as surrogates for humans, are an excellent means to assess internal 89 
exposure of PAHs. Swine have become a popular human exposure model, and have been 90 
validated as a model for lead and arsenic (Casteel et al., 2006, Juhasz et al., 2008), as well as 91 
gaining popularity for organic compounds like PAHs (Duan et al., 2014, James et al., 2011, 92 
Peters et al., 2015). Swine are an alternative model to rodents due to the similarities between 93 
swine and humans in gastrointestinal physiology and intestinal conformation, as well as the 94 
cellular make-up of the organs (Patterson et al., 2008). Biochemically, swine AhR response to 95 
agonists like PAHs manifests very similar in magnitude to that of humans (Lesca et al., 1994). 96 
 Assessing internal exposure of parent compounds in an animal that ingests contaminated 97 
soils allows us to directly external to internal exposure of PAHs.  It is widely assumed that 98 
external and internal exposure will follow a linear trend.   Bioavailability is the slope of internal 99 
to external exposure.  However, toxicologists, especially those concerned with mutagens, have 100 
long recognized that their dose-response relationships are typically hockey-stick shaped.  A 101 
hockey-stick dose-response relationship comprises a linear and a sub-linear component, with 102 
typically the sub-linear component occurring at lower doses.  Thus, for example low doses of a 103 
mutagen may cause no adverse effect until a break point is reached, at which point adverse 104 
effects increase linearly with dose.   Commonly, models such as a benchmark dose (BMD), or a 105 
threshold dose (Td) model is used for such datasets(Gollapudi et al., 2013). Both Td and BMD 106 
calculations utilize the entire dose-response data set and interpolate the data to derive a point of 107 
departure where the response begins to differ significantly from the control.  In other words, this 108 
approach allows one to estimate two slopes in a biphasic relationship.  It is exactly this type of 109 
relationship, we observed in this study.   110 
Materials and Methods 111 
Soils 112 
 Artificial soil was prepared and spiked as in Peters et al. (2015). Soil spiked with BaP and 113 
anthracene resulted in swine exposure of 1, 5, 10, and 20 mg kg-bw-1 to each compound in 5 g of 114 
soil. Soot was provided by the Meyer lab group at the Technical University of Denmark. More 115 
detailed information on the soot, as well as swine bioavailability is available in Gouliarmou et al. 116 
(2015). Here we only present data from BaP and anthrancene from that data set.  In short, a 117 
composite soot sample collected from several wood-burning stoves in a small Danish town near 118 
Roskilde was divided into two treatment groups, with one group of soot treated in contaminant 119 
traps, while the other remained untreated. Treated and untreated soot were combined in different 120 
ratios to create various PAH concentrations. Soot exposures were designated Soot 1, Soot 2, Soot 121 
3, and Soot 4, and contained 100% untreated soot, 50% treated and 50% untreated soot, 17% 122 
treated and 83% untreated soot, and 100% untreated soot respectively. Soils collected from PAH 123 
impacted sites in the United Kingdom (n=12), Sweden (n=2), and Canada (n=5) were also fed to 124 
swine for a total of 4 artificial soil, 19 real-world soil, and 4 soot exposures. 125 
 PAHs in the real-world soils were extracted by an ultrasonication method. Briefly, 5 ml 126 
of 1:6 toluene:methanol solvent mix was added to 1 g of soil. The slurry was sonicated for 2 127 
hours, centrifuged for 15 min at 3000 g, passed through a 0.45 µm filter, and stored at -20 ˚C 128 
until analysis. Anthracene and BaP concentrations in the soot and soils are presented in Table 1. 129 
IV Dose 130 
 The intravenous dose was prepared by completing a solvent transfer of a PAH calibration 131 
standard containing 16 different PAHs (Supelco PAH Calibration Mix, 10 µg/ml in acetonitrile, 132 
Sigma Aldrich) into glyceryl trioctanoate (Sigma Aldrich). Briefly, four 1 ml calibration 133 
standards were combined and the acetonitrile was evaporated to near dryness under a stream of 134 
high purity nitrogen gas, after which 10 ml of diethyl ether was added. Approximately half the 135 
diethyl ether was evaporated under a stream of high purity nitrogen gas, 1 ml of glyceryl 136 
trioctanoate added, and the remaining diethyl ether evaporated. 137 
Swine 138 
Female Landrace cross pigs (7-8 weeks in age) were obtained and housed at the Prairie 139 
Swine Centre in Saskatoon, SK. Swine were housed in individual pens and allowed 7 days to 140 
acclimate prior to exposure. During the acclimation period, staff trained swine to eat a dough ball 141 
consisting of flour, molasses, pig chow, and vanilla. Swine were maintained on standard grower 142 
ration at 4% body weight and given water ad libitum. Swine were divided into groups (n=6) and 143 
exposed to PAHs by either IV or oral routes, as outlined below. Animals were monitored daily 144 
during the exposure study by trained animal care staff, and were not observed to suffer ill effects 145 
from exposure to PAHs. The study was reviewed and approved prior to initiation by the 146 
University of Saskatchewan Animal Care and Ethics Committee (Animal Use Protocol Number: 147 
20080153). 148 
Exposure Study 149 
 In order to maximize the data generated by each pig, swine experienced multiple 150 
exposures to PAHs in dose media. This was done by exposing swine to a single dose of PAHs, 151 
either through oral (i.e. soil or soot) or IV exposure, generating a 48 hour plasma time course, 152 
and allowing a 7 day washout period before subsequent exposure. Swine were dosed over a 153 
period of 5 weeks, and euthanized at the end of the experiment.  154 
Oral Exposure 155 
Swine were given approximately 5 g of soil or 7 g of soot in a dough ball consisting of 156 
flour, molasses, pig chow, and vanilla. The soil or soot was added to the dough ball along with 157 
the addition of the flour. Swine were allowed to eat the dough ball passively, and generally 158 
consumed it in less than a minute. If the dough ball was not consumed within 10 min, the swine 159 
were restrained and the dough ball force fed to the pig. 160 
IV Exposure 161 
Swine were moved to a dedicated IV dose area and restrained with a hog snare and 162 
handling board. A 1.5 inch, 20 gauge catheter was inserted into an ear vein following topical 163 
application of lidocaine to numb the skin. The IV dose media containing PAHs (1 ml) was 164 
injected through the catheter, and the catheter flushed with saline. The catheter was removed 165 
immediately after the injection was completed, and pressure applied to the injection site until 166 
bleeding had stopped. After bleeding ceased, the animals were returned to their individual pens. 167 
Blood Collection and Analysis 168 
 Whole blood was collected from the jugular vein of four swine per treatment group at 0, 169 
2, 4, 6, 8, 12, and 24 hours post-exposure into heparinized vacutainers. Sample collection was 170 
limited to four swine per time point to minimize physical trauma to the animal caused by 171 
restraint and blood collection. Blood was stored at 4˚C until plasma separation by centrifugation 172 
(1000 rpm for 15 min) and plasma stored at -20˚C until extraction. Plasma was extracted by solid 173 
phase extraction, as in James et al., (2011), and stored at -20˚C until analysis. 174 
High Pressure Liquid Chromatography 175 
 Plasma and soil extract was analyzed by high pressure liquid chromatography coupled 176 
with fluorescence detection (HPLC-FD) using an Agilent 1260 Infinity system. A 10 µL aliquot 177 
of extract was injected on an Agilent PAH Pursuit column (3 µm particle size, 100 mm length, 178 
and 4.6 mm inner diameter) guarded by an Agilent MetaGuard 3 µm C18 4.6 mm column. The 179 
column was kept at 25˚C during use by a column heater. Run time was set at 30 min and HPLC 180 
grade water and acetonitrile (ACN) used as the solvents. The initial solvent gradient was 60:40 181 
ACN:water, with a linear shift to 90:10 ACN:water between 0 min and 20 min. The 90:10 182 
ACN:water gradient was maintained for 5 min, then the gradient was returned to 60:40 183 
ACN:water for 5 min to re-equilibrate the column for the next sample. The Agilent 1260 system 184 
was equipped with multisignal acquisition; therefore the excitation wavelength was set at 260 185 
nm, while the 4 fluorescence detectors were set for emission wavelengths of 350 nm, 420 nm, 186 
440 nm, and 500nm respectively. 187 
Quality Assurance and Control 188 
 Plasma collected at the 0 hour time point was analyzed and used to correct the analytical 189 
results from the plasma of the PAH exposed swine. Duplicates, blanks, and spikes were also 190 
completed as part of the QAQC process. The average percent deviation of analytical duplicates 191 
for swine samples was 18%. Average spike recovery from plasma during the solid phase 192 
extraction process was 70%, and from the ultrasonication extraction process for soil was 94%. 193 
The HPLC-FD was calibrated using dilutions of an external standard consisting of 10 µg/mL of 194 
each PAH and the calibration updated daily. Limits of detection for the HPLC-FD were 0.97 195 
ng/mL for anthracene and 1.74 ng/mL for BaP. Plasma concentrations were corrected for 196 
partitioning of PAHs into whole blood components, and the average recovery for anthracene and 197 
BaP in plasma compared to whole blood were 42% and 43% respectively. 198 
In order to determine if the washout period of 7 days was adequate to allow metabolic 199 
processes to return to baseline levels between exposures, one group of swine was exposed to the 200 
same soil in week 1 of exposure, as well as week 5, and calculated bioavailabilities were 201 
compared. No statistically significant difference was observed between exposure weeks (data not 202 
shown). 203 
Pharmacokinetic Parameter Calculations 204 
Area Under the Curve 205 
 Area under the curve (AUC) calculations were completed on the plasma concentration 206 
time course for each compound in individual pigs. AUC calculations are assumed to represent 207 
the total body exposure to a compound following an oral dose. AUC was calculated to the 24 208 
hour time point with the MESS package (Ekstrom, 2012) in statistical program R (R Team, 209 
2011) using the trapezoidal rule.  210 
Absorption and Elimination Rates 211 
 Absorption (ka) and elimination (kel) rates were calculated for each compound in each 212 
soil group as factors of the absorption and elimination slopes in the plasma concentration time 213 
course. The absorption rate was calculated using the residual method, and the elimination rate 214 
was calculated as the slope of the elimination phase of the log plasma concentration time course. 215 
Both rates were calculated using PKSolver, an open-source Microsoft Excel add-in (Zhang et al., 216 
2010). Data for individual swine were pooled for each exposure group as blood samples were not 217 
collected from each pig at all time points. Thus, standard error was not calculated for absorption 218 
and elimination rate constants. 219 
Bioavailability 220 
 Bioavailability for spiked artificial soil was calculated as the slope of the AUC vs soil 221 
concentration relationship. Bioavailability for IV exposure was calculated by dividing the area 222 
under the plasma time course by the total exposure (Equation 1). 223 
???? ? ???????????          Equation 1 224 
Absolute bioavailability of spiked soil was calculated by dividing spiked soil bioavailability by 225 
BAIV, as in Equation 2. 226 
????? ? ??????????           Equation 2 227 
Point of Departure Calculations 228 
Threshold Effect Level 229 
 Threshold effect level values were calculated using a piecewise linear model. This model 230 
defines a linear relationship for both the low and high part of the dose-response curve, as well as 231 
an unknown knot point at the threshold dose. 95% upper and lower confidence intervals were 232 
calculated for the threshold by bootstrap analysis. The 95% lower confidence interval is typically 233 
reported as the point of departure. This model is available as part of the SiZer package 234 
(Sonderegger, 2015) for the statistical software program R  (R Team, 2011). The initial slope of 235 
the line below the point of departure, along with 95% confidence intervals of the slope, is also 236 
calculated with this model.  237 
Benchmark Dose 238 
 Benchmark doses (BMD) are calculated by fitting models to the dose-response data and 239 
using a predetermined response level, commonly 10% from background, to select a BMD. BMD 240 
values were determined using the US EPA Benchmark Dose Software (BMDS) Version 2.5, 241 
(http://www.epa.gov/ncea/bmds/). This software contains 30 different models that can be used to 242 
calculate a BMD. The exponential model for continuous data was chosen for this data as it 243 
provided the best fit. The lower bound 95% confidence limit on the BMD (BMDL) was also 244 
calculated, and this value is typically reported as the point of departure. The exponential model 245 
does not calculate a sub-linear slope for the data. 246 
Results and Discussion 247 
 Swine anthracene and BaP AUC values following a single exposure to real world soils 248 
did not demonstrate a correlation with soil concentration of PAHs (Figure 1, anthracene: r2=0.14, 249 
p=0.54; BaP: r2=0.13, p=0.56). The highest soil concentration of anthracene and BaP (BGS 12) 250 
was not included in the regression as it exhibited excessive leverage. Total soot and soil 251 
anthracene doses ranged from 0.04 µg to 724 µg and averaged 66 (32) µg, while total BaP doses 252 
ranged from 0.01 µg to 1450 µg and averaged 188 (64) µg.  As no relationship was found 253 
between real-world soils and internal exposure, average anthracene and BaP AUCs were 254 
calculated (standard error (SE) in brackets). Anthracene AUCs ranged from 0.61 µg hr L-1 to 255 
14.4 µg hr L-1 and averaged 3.6 (0.6) µg hr L-1, while BaP AUCs ranged from 1.0 µg hr L-1 to 256 
7.2 µg hr L-1 and averaged 2.6 (0.4) µg hr L-1.  257 
In contrast to real world soils, BaP and anthracene AUCs generated from swine exposed 258 
to spiked artificial soil strongly correlated with soil concentration (Figure 1). Linear regressions 259 
completed for both anthracene and BaP demonstrated AUC has a high dependence on soil 260 
concentration (anthracene: r2=0.99, p=0.007; BaP: r2=0.95, p=0.02).  The strong linear 261 
relationship at high doses indicates that absorption in the swine model was not limited by 262 
concentration of PAHs in soil. Bioavailability of anthracene and BaP was very low from spiked 263 
artificial soil, and was found to be 0.7% and 0.5% respectively. Absolute bioavailability was also 264 
determined, and calculated as 1.2% for anthracene and 0.7% for BaP. 265 
 266 
Analysis of the biphasic external to internal exposure relationship 267 
The shift from no relationship between AUC and dose in real-world soils to a strong 268 
linear relationship between AUC and dose in spiked soils may occur because of biochemical 269 
interactions between uptake and soil PAH concentration. PAHs are taken up concurrently with 270 
lipids (Stavric and Klassen, 1994), and as such, may be conveyed to systemic circulation via 271 
lipid transporters in the gastrointestinal tract. The dose swine were exposed to in the real-world 272 
soil study may have been too low to actively compete for transfer via these transport proteins, 273 
while the spiked artificial soil had a much higher PAH concentration, and therefore may have 274 
had better success competing for transport. Alternatively, the linear dose-AUC relationship in 275 
spiked soil exposed swine may result from passive diffusion playing a more active role as PAH 276 
concentrations increased. Clearance mechanism saturation may occur in the body with higher 277 
exposures, which would lead to proportional increases in internal exposure to PAHs.  In contrast, 278 
these clearance mechanisms may sufficiently clear PAHs before their entrance into systematic 279 
circulation following real-world soil exposure.  280 
Point of Departure (POD) modeling of AUC versus soil concentration indicated AUC did 281 
not increase until soil concentration values greatly exceeded those typically seen in naturally 282 
PAH-impacted soil. PODs calculated using the US EPA Bench Mark Dose Software (BMDS) 283 
were 10,700 mg kg-1 and 4,500 mg kg-1 for anthracene and BaP respectively. Alternatively, 284 
piecewise regression resulted in PODs of 7,500 mg kg-1 for anthracene and 1,900 mg kg-1 for 285 
BaP. This analysis would suggest that below these concentrations, there is a limited link between 286 
external dose and internal exposure. However, there are limitations associated with the data 287 
generated from spiked artificial soil, namely weathering time. Soil collected from real-world 288 
sites had experienced significant weathering time prior to collection, while the spiked artificial 289 
soil had only a few weeks of weathering. Additionally, the gap between real-world and spiked 290 
soil concentrations was very large, and as such, may skew the POD models. 291 
Toxicokinetic parameters of PAHs ingested with soil 292 
Like AUCs, anthracene absorption rate constants (ka) calculated in swine exposed to real-293 
world or spiked artificial soils do not correlate to soil concentration, while BaP ka values weakly 294 
do (Figure 2, anthracene: r2=0.01, p=0.64; BaP: r2=0.26, p=0.03). Absorption rate constants 295 
calculated for spiked artificial soils remained fairly constant, and the range of calculated values 296 
did not differ greatly from those calculated for real-world soils. Average ka values calculated for 297 
combined artificial and real-world soils were 2.8 (0.7) hr-1 and 3.7 (0.7) hr-1 for anthracene and 298 
BaP respectively. 299 
Both anthracene and BaP ka values calculated in swine compare to the range of available 300 
literature PAH ka values for rodents. Absorption rate constants reported in both rats and mice, for 301 
benzo[a]anthracene, pyrene, and phenanthrene, range from 0.69 hr-1 to 18.8 hr-1 (Kadry et al., 302 
1995, Withey et al., 1991, Modica et al., 1983). The highest reported ka of 18.8 hr-1 was found in 303 
rats exposed to 4 mg kg-1 pyrene in a study consisting of a range of doses from 2 mg kg-1 to 15 304 
mg kg-1, and this value was much larger than the other reported ka values for other doses from 305 
the same study (Withey et al., 1991). If we exclude this value, the highest reported ka value is 5.0 306 
hr-1, from Withey et al. (1991). Further, Kadry et al. (1995) reported similar ka values for 307 
phenanthrene between exposure media after oral exposure from neat compound, as well as 308 
spiked clay and sand (0.69 to 1.4 hr-1). 309 
Like ka, calculated elimination rate constants (kel) for the artificial and real-world soils 310 
did not show any correlation with soil compound concentration (data not shown). Therefore, kel 311 
values in orally exposed swine were averaged for real-world and artificial soils and the average 312 
anthracene kel was 0.54 (0.2) hr-1, and the average BaP kel was 1.4 (0.4) hr-1. Elimination rate 313 
constants calculated following IV exposure for both anthracene and BaP were found to be 5.3  314 
hr-1 and 3.7 hr-1 respectively. 315 
Calculated kel values for both anthracene and BaP in orally exposed swine compare to 316 
published rodent kel values for oral exposure; however, the calculated kel values for swine tended 317 
to fall on the high end of the reported range. Published pyrene, benzo[a]anthracene, 318 
phenanthrene, and BaP kel values for both rats and mice range from 0.02 hr-1 to 1.3 hr-1 (Kadry et 319 
al., 1995, Modica et al., 1983, Ramesh et al., 2001, Withey et al., 1991, Uno et al., 2004). Two of 320 
these studies contain BaP kel values, with widely variable results reported: 0.12 hr-1 by Ramesh 321 
et al. (2001), and 1.3 hr-1 by Uno et al. (2004). These two studies were conducted in different 322 
species (rats and mice respectively), which may account for the variability in reported kel values. 323 
As with oral exposure, swine kel values after an IV exposure exceeded published values. 324 
Elimination rate constants found in literature for IV exposure of pyrene and BaP range from 325 
0.173 hr-1 to 3.5 hr-1 (Withey et al., 1991, Bouchard et al., 1998, Lipniak-Gawlik, 1998, Moir et 326 
al., 1998). Moir et al. (1998) evaluated the kinetics of BaP in rats over a range of doses, and 327 
reported kel values ranging from 0.98 hr-1 to 2.85 hr-1, the maximum of which is similar to the 328 
BaP kel  for swine in this study. Additionally, Lipniak-Gawlik (1998) investigated the influence 329 
of other PAHs on pyrene kinetics, and demonstrated that mixtures of PAHs may affect the 330 
toxicokinetics of a compound. 331 
Physiological explanation of low dose responses 332 
Differences in IV and oral exposure elimination kinetics provide the clue to explain why 333 
external exposure is not linked to internal exposure at low PAH concentrations.  The differences 334 
between IV an oral suggest that flip-flop kinetics is occurring.  Flip-flop kinetics occur when the 335 
gastrointestinal absorption rate is slower than the elimination rate of a compound (Yanez et al., 336 
2011). Flip-flop kinetics reduce systemic parent compound exposure as the compound 337 
metabolizes at a faster rate than it is absorpted (Zhu et al., 2000). Work previously published by 338 
Withey et al. (1991), and Viau et al. (1999) report that elimination kinetics of  pyrene following 339 
an IV and oral exposure do not differ significantly. However, both studies used a liquid carrier, a 340 
saline/emulphor mix and glucose/emulphor mix respectively, for the oral exposure of pyrene. In 341 
this study, the soil matrix may limit gastrointestinal absorption of PAHs, and therefore induce 342 
flip-flop kinetics. This phenomenon may explain the lack of difference seen in AUC 343 
measurements from various real-world soils as parent PAHs would be cleared very quickly 344 
following absorption. 345 
Anthrancene AUCs weakly correlate to anthracene partitioning from soil in simulated 346 
intestinal fluid (r2=0.18, p=0.13, Figure 3). BaP bioavailability (AUC normalized to dose) also 347 
correlates weakly with Forest fluid partition co-efficients (James et al., 2015). Both anthracene 348 
and BaP demonstrate negative relationships with Forest fluid partitioning co-efficients – as the 349 
partitioning co-efficient increases, AUC and bioavailability decrease. Partitioning co-efficients 350 
represent the ratio of compound in soil to compound in fluid; therefore, partitioning co-efficients 351 
increases signify a greater proportion of compound remaining in soil, rather than fluid. Thus, 352 
increases in simulated GI fluid partitioning values indicate a stronger affinity of the compound, 353 
whether anthracene or BaP, to the soil particles, and explains the negative relationship with 354 
AUC. 355 
Options for the risk assessment of contaminated soils 356 
 We propose four PAH risk assessment options: (i) assume 100% bioavailability, (ii) 357 
assume constant internal exposure below 1,900 mg kg-1, (iii) assume <100%, e.g. 21%, 358 
bioavailability below 1,900 mg kg-1, or (iv) model internal exposure through AUC versus soil 359 
characteristic relationships.   The most conservative, but least accurate, method of risk 360 
assessment for PAH impacted sites assumes that 100% of ingested PAHs transfer into an 361 
organism. As demonstrated in this study, as well as others, PAH bioavailability can vary widely 362 
depending on dose media, and may lie below 1% in soil (James et al., 2015, Peters et al., 2015, 363 
Ramesh et al., 2004). Therefore, this method may result in extremely elevated risk values for 364 
impacted sites. 365 
The second risk assessment option assumes humans absorb a constant amount of PAHs in 366 
contaminated soil, irrespective of the contaminant level in these soils.  The Incremental Lifetime 367 
Cancer Risk (ILCR) is calculated by multiplying the external compound dose to the appropriate 368 
cancer slope factor (CSF). Thus, if we assume that internal dose is not linked to external dose, 369 
then using average BaP AUC value from our study, corrected for assumed adult and toddler soil 370 
ingestion rates (CCME, 2006), the ILCR is 6.2x10-6 for adults and 1.6x10-6 for toddlers. In 371 
contrast, if we assume 100% bioavailability and the average BaP concentration of our soils, the 372 
ILCR is 2.3x10-5 for adults and 3.9x10-4 for toddlers.   Although this approach is very simple, it 373 
does not incorporate site-specific variations, and as such, may not accurately represent risk. 374 
The third risk assessment option calculates bioavailability as the slope of the internal-375 
exposure dose curve at environmentally relevant soil concentrations.  At these low 376 
concentrations, this slope is often termed the sublinear portion because it is not significantly 377 
different from zero. Piecewise regression of this sublinear portion indicates that bioavailability 378 
estimates for environmentally relevant soil concentrations range from 1.6% to 21% for BaP and 379 
0% to 21% for anthracene (Table 3). However, these approaches are highly sensitive to the 380 
spiked soil doses, the limitations of which were discussed previously. Thus, our estimate of 21% 381 
soil BaP concentration becoming bioavailable may be too inaccurate to use at a contaminated 382 
site.   383 
The fourth, and final, option is to use partitioning to estimate internal exposure of PAHs 384 
to humans.  For example, in Figure 3, there is a weak relationship between partitioning and 385 
AUC. This approach can internal exposure estimates to site-specific soils but requires site-386 
specific data.  Additionally, the observed correlations between partitioning co-efficients and 387 
internal exposure in swine were very weak, and as such, may be inaccurate. 388 
Synopsis 389 
Analysis of swine anthracene and BaP toxicokinetics demonstrated PAH soil 390 
concentration does not influence internal exposure of PAHs. This contradicts the common 391 
assumption in risk assessment that risk relates linearly to the soil concentration, and therefore 392 
external dose, of a compound. There appears to be a point of departure in soil concentrations 393 
where internal exposure and external dose become related. Using two different point of departure 394 
models indicated AUC and soil dose were only linked at soil concentrations much larger than 395 
those typically seen in PAH impacted soils found in the environment. Thus, it may be reasoned 396 
humans are exposed to a constant internal dose of PAHs, regardless of external dose. We 397 
hypothesize this occurs because of limited absorption coupled with rapid elimination, leading to 398 
a reduced amount of circulating compound. As this study measured parent PAHs in systemic 399 
circulation as an indication of internal exposure, decreases in circulating compound would lead 400 
to a decreased apparent internal exposure.  However, our study design cannot speak to the risk of 401 
exposure of the gastrointestinal lining, as PAH exposure to this tissue occurs during the 402 
absorption phase, independent of systemic circulation. 403 
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Figure 1. The calculated AUC values for anthracene and benzo[a]pyrene in swine after a single 409 
exposure to spiked artificial and impacted real-world soil versus the concentration of anthracene 410 
and benzo[a]pyrene in soil. Error bars represent the standard error of the mean for both soil 411 
concentration (horizontal, n=3) and AUC (vertical, n=6). Linear regression for impacted real-412 
world soils and soot (inset) did not demonstrate a correlation between AUC and soil 413 
concentration for either anthracene (r2=0.14, p=0.54) or benzo[a]pyrene (r2=0.13, p=0.56). 414 
However, linear regression for the spiked soils demonstrated a correlation between AUC and soil 415 
concentration for both anthracene (r2=0.99, p=0.007) and benzo[a]pyrene (r2=0.95, p=0.02).416 
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Figure 2. Absorption rate constants for anthracene and benzo[a]pyrene in swine following a 418 
single exposure to one of 19 real-world soils or 4 spiked artificial soils versus soil concentration. 419 
A linear regression was completed for both benzo[a]pyrene and anthracene, and a significant 420 
correlation was not observed for either compound for real-world soils (anthracene: r2=0.014, 421 
p=0.64; benzo[a]pyrene:  r2=0.26, p=0.03) or spiked soils (anthracene: r2=0.01, p=0.84; 422 
benzo[a]pyrene: r2=0.02, p=0.81).   423 
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Figure 3. Anthracene AUC in swine (n=6) orally exposed to PAHs in real-world impacted soils 426 
(n=14) versus log of simulated intestinal fluid partitioning co-efficient. Linear regression 427 
demonstrated a weak correlation between variables (r2=0.18, p=0.13).  428 
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Table 1. Measured soil concentrations of anthracene and benzo[a]pyrene in real-world soils 429 
given to swine. Standard error is in brackets. 430 
Soil  Anthracene 
(mg kg-1) 
Benzo[a]pyrene 
(mgkg-1) 
WP1 27 (2.4) 18 (1.7) 
GW5 1.1 (0.02) 4.5 (0.08) 
Soot 1 2 10 
Soot 2 5.5 25 
Soot 3 7.8 35 
Soot 4 9 40 
BGS 1 1.6 (0.07) 2.5 (0.3) 
BGS 2 11 (0.7) 56 (2.6) 
BGS 3 12 (0.6) 55 (2.9) 
BGS 4 11 (0.5) 61 (2.4) 
BGS 5 5.7 (0.1) 27 (0.3) 
BGS 6 4.8 (0.2) 17 (0.2) 
BGS 7 3.4 (0.1) 9. 9 (0.2) 
BGS 8 4.1 (0.04) 37 (0.4) 
BGS 9 2.6 (0.07) 22 (1.2) 
BGS 10 17 (3.3) 41 (8.9) 
BGS 11 11 (0.1) 48 (0.8) 
BGS 12 144 (5.0) 290 (5.8) 
COT 1 0.008 (0.003) 0.12 (0.1) 
COT 2 0.009 (0.004) 0.014 (0.0005) 
COT 3 0 (0) 0 (0) 
COT 4 0.013 (0.0008) 0.009 (0.005) 
COT 5 0.012 (0.0004) 0.002 (0.0006) 
 431 
Table 2. Pros and Cons of Risk Assessment Options for PAHs 432 
Option Pros Cons 
100% bioavailability Simple, conservative May overestimate risk 
Constant AUC Simple, likely realistic Not site-specific 
Constant (<100%) 
bioavailability Simple 
Highly dependent on spiked soil 
concentrations, may not be 
accurate 
Soil:fluid partitioning Site Specific 
More complex, weak 
correlation, more labour 
intensive 
  433 
Table 3. Estimated bioavailability of BaP and anthracene from piecewise regression modeling 434 
Compound 
Average 
Bioavailability 
(%) 
Lower 95% 
Confidence Interval 
Upper 95% 
Confidence Interval 
Anthracene 6.1 0 21 
Benzo[a]pyrene 12 1.6 21 
  435 
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